Citi Upgrades Mirati Therapeutics (MRTX) to Buy

Citi upgraded Mirati Therapeutics (NASDAQ: MRTX) from Neutral to Buy with a price target of $48.00.

For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.

Shares of Mirati Therapeutics closed at $26.44 yesterday.

You May Also Be Interested In

• Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'
• BMO Capital Upgrades Park Hotels & Resorts (PK) to Outperform
• Goldman Sachs Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Buy